Core Laboratories (CLB) Common Equity (2022 - 2026)

Core Laboratories' Common Equity history runs 5 years deep, the most recent figure standing at $268.9 million for Q1 2026.

• On a quarterly basis, Common Equity rose 5.89% year-over-year to $268.9 million in Q1 2026; TTM through Mar 2026 was $268.9 million, a 5.89% increase from a year earlier, with the FY2025 full-year figure at $272.2 million, up 7.88% from the prior year.
• Common Equity slipped to $268.9 million in Q1 2026 per CLB's latest filing, from $272.2 million in the prior quarter.
• Across five years, Common Equity topped out at $272.2 million in Q4 2025 and bottomed at $173.8 million in Q2 2022.
• The 5-year median for Common Equity is $241.6 million (2024), against an average of $233.7 million.
• Across the five-year window, Common Equity climbed 26.38% in 2023 and climbed 5.82% in 2025, its largest moves.
• Year by year, Common Equity stood at $183.5 million in 2022, then rose by 22.26% to $224.4 million in 2023, then increased by 12.45% to $252.3 million in 2024, then gained by 7.88% to $272.2 million in 2025, then slipped by 1.22% to $268.9 million in 2026.
• Per Business Quant, the three latest CLB Common Equity figures stand at $268.9 million (Q1 2026), $272.2 million (Q4 2025), and $271.3 million (Q3 2025).